ChromaDex Corporation Stock News

ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infect

ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen® (nicotinamide riboside or NR) in bolstering cellula

ChromaDex Corp. (NASDAQ:CDXC) today announced the results of multiple new preclinical studies that illustrate the multifaceted potential of Niagen® (n

The following slide deck was published by ChromaDex Corporation in conjunction with this event.

Chromadex (NASDAQ:CDXC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday, Zacks.com reports. The firm currently has a $5.25 price

Chromadex (NASDAQ:CDXC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports. According to Zacks, “Chroma

ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world’s most respected quality management standard. This accreditation c

ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world’s most respected q

June 18 Event Spotlights Paycheck Protection Program Loan Forgiveness, Other Regulatory Developments NEW YORK--(BUSINESS WIRE)--#cares--Wolters Kluwer Compliance Solutions is hosting an informational

ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 a

ChromaDex Corp. (NASDAQ:CDXC), a global scientific authority on nicotinamide adenine dinucleotide (NAD) and innovators behind Niagen® (patented nicotinamide riboside) science, announced today the pub

ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Invest

Zacks Investment Research upgraded shares of Chromadex (NASDAQ:CDXC) from a hold rating to a buy rating in a report published on Thursday morning, Zacks.com reports. Zacks Investment Research currentl

BlackRock Inc. decreased its stake in shares of Chromadex Corp (NASDAQ:CDXC) by 0.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,467,860 shares